Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
To observe the efficacy and safety of hydrochloride anlotinib combined with concurrent
radiochemotherapy for patients with FIGO stage IB3 and IIA2-IVA cervical cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University